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Abstract
Diabetic polyneuropathy (DPN) pathophysiologic findings include loss of multifocal
and focal nerve fibers secondary to axonal degeneration and segmental demyelization
due to oxidative stress and mitochondrial dysfunction induced by chronic hypergly‐
caemia.
Aim: To evaluate the effect of ubiquinone, ezetimibe/simvastatin and rosuvastatin on
mitochondrial function in patients with diabetic polyneuropathy.
Methods: A randomized, double‐blinded, placebo‐controlled clinical trial was
performed in patients with type 2 Diabetes Mellitus (T2DM) who had DPN, glycated
haemoglobin (HbA1c) <12% (108 mmol/mol), previous exclusion of other type of
neuropathy. Ninety‐eight persons with T2DM were enrolled allocated 1:1:1:1 to either
placebo, ubiquinone 400 mg, ezetimibe/simvastatin 10/20 mg or rosuvastatin 20 mg for
16 weeks. Primary outcomes were F0F1‐ATP hydrolysis, erythrocyte and sub‐mito‐
chondrial platelet membrane fluidity. Results were expressed as mean ± SD or SEM and
percentages.
Results: F0F1‐ATP hydrolysis levels in healthy controls were 236.80±118.42 nmol/PO4;
all patients with T2DM exhibited an increase, but only rosuvastatin demonstrated an
improvement with baseline 463.37±47.07 nmol/PO4 vs. after 340.61±37.80 nmol/PO4
treatment (p<0.05). Plasma and sub‐mitochondrial membrane fluidity did not experi‐
ence any significant changes.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
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Conclusions: Rosuvastatin was found to improve mitochondrial function by reducing
F0F1‐ATP hydrolysis. No changes in sub‐mitochondrial platelets particles or erythro‐
cytes ghosts were found.
Keywords: ubiquinone, statins, diabetic polyneuropathy, oxidative stress, mitochon‐
drial dysfunction
1. Introduction
Nerve dysfunction system in patients with diabetes is known as diabetic neuropathy and is
considered as the most prevalent microvascular complication—up to 60%—in diabetes
mellitus (DM) subjects [1]. Diabetic polyneuropathy (DPN) comprise ≈70% of all cases [2].
Diabetic sensorimotor polyneuropathy is the most common for these complications, occurring
in patients with type 1 and 2 diabetes mellitus, as well as in those with prediabetes and glucose
intolerance [3]. Its diagnosis is established by means of validated scores based on clinical
features and abnormal nerve conduction studies (NCS) [4]. Pathophysiologic findings include
loss of multifocal and focal nerve fibers secondary to axonal degeneration and segmental
demyelization, basically due to oxidative stress and mitochondrial dysfunction induced by
chronic hyperglycemia, which leads to neural apoptosis [5, 6]. Mitochondrial dysfunction leads
to free radical excessive production through imbalance between hydrogen ions and electron
transport carriers, which takes place in the inner mitochondrial membrane and could be
evaluated indirectly by membrane fluidity and F0F1‐ATPase hydrolysis [7, 8].
Ubiquinone (coenzyme Q10) is a potent antioxidant acting as an electron carrier in the
mitochondrial electron transport chain, thus reducing free radical production with high
concentrations present in high metabolic activity tissues such as heart, kidney, liver, and
skeletal muscle [9]. Ezetimibe diminishes cholesterol ester content in chylomicrons by reducing
liver cholesterol intake that in consequence increases LDL uptake and plasma depuration;
when combined with simvastatin, cholesterol reduction is potentially increased [10]. Pleio‐
tropic effects of statins include an increase in nuclear factor kappa B activity and amelioration
of superoxide (O2–) ions after 12‐week treatment [11]. Another HMG‐CoA inhibitor, rosuvas‐
tatin, has an antioxidant effect by acting as free radical carrier diminishing mitochondrial and
cellular Lipid peroxidation (LPO) production [12].
We conducted this study to evaluate the effect of ubiquinone, ezetimibe/simvastatin, and
rosuvastatin on mitochondrial function in patients with DPN.
2. Subjects, materials, and methods
2.1. Study design
A randomized, double blinded, placebo controlled phase II clinical trial was performed in the
Clinic and Experimental Therapeutics Institute, University of Guadalajara, Mexico. Subjects
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were assigned to four group treatments by blocks with a parallel sequence 1:1:1:1 by means of
a randomized computer‐based list, generated by a different researcher who was unaware of
drugs given to patients. Patients were divided into the following groups: control group that
received placebo and three experimental groups that were assigned to ubiquinone, ezetimibe/
simvastatin, and rosuvastatin as a daily single dose for 16 weeks.
2.2. Study population
Participants were eligible based on Dyck et al. characteristics for DPN [4]. Inclusion criteria
were subjects ≥18 years old, T2DM (T2DM) according to ADA (American Diabetes Association)
criteria, HbA1c <12%, and informed consent signed. Patients were excluded if they had renal
or hepatic failure, pregnant or nursing women, and other neuropathies rather than diabetic
(alcohol‐induced, radiculopathy, autoimmune, cancer‐related). They were eliminated once
admitted if lack of adherence to treatment evaluated when <80% of drug intake, and/or severe
adverse drug reaction. Patients were selected by invitation in forums, outpatients recruited
from primary care clinics, and database collected previously by our research Institute,
Guadalajara residents from February 2010 to 2012. Patients were instructed to take their drugs
only by night at the same time every day as follows: placebo 100 mg, ubiquinone 400 mg,
ezetimibe/simvastatin 10/20 mg, and rosuvastatin 20 mg. All drugs were similar in physical
characteristics and presented in dark vials, carefully filled by another group researcher who
placed a respective tag with the patient code. Moreover, patients were provided with a diary
where they could write down the date and time of drug administration, and drug adverse
reactions felt. Such information was collected and registered after every 4 weeks. Primary
outcomes were mitochondrial function parameters: F0F1‐ATPase hydrolysis, erythrocyte
ghosts, and submitochondrial platelet membrane fluidity. We also measured other metabolic
and safety measures: fasting glucose, HbA1c, total cholesterol, high and low density lipopro‐
teins (HDL, LDL), and triglycerides. Safety profile was assessed with drug adverse reactions,
renal (urea, creatinine), and hepatic [alanine and aspartate aminotransferase (ALT, AST),
gamma glutamil‐transferase (GGT), and bilirubin and phosphokinase (CPK)] laboratory
variables.
2.3. Healthy subjects
We included an additional group consisting of nine subjects randomly selected from a
preventive medicine first contact clinic to establish a cutoff point for the below‐mentioned
parameters. Healthy age and sex‐matched volunteers without DM were included in the control
group.
2.4. Mitochondrial function markers
Hydrolytic activity of mitochondrial F0F1‐ATPase was obtained by spectrophotometry, from
release of inorganic phosphate in serum samples of platelets isolated according to the method
described by Baracca et al. [13]. Thirty microliters of the sample and 20 μL of ATP (100 mM)
were added to 1 mL of ATPase buffer [125 mM KCl, 40 mM of Mops (pH 8), 3 mM MgCl2],
and then agitated, followed by incubation at 40°C for 10 minutes. ATPase activity was stopped
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with 200 μL of 30% trichloroacetic acid, and samples were centrifuged for 10 minutes at 3500
rpm. Then, 1 mL of 3.3% ammonium molybdate and 100 μL of 10% ferrous sulfate were added
to 800 μL of the supernatant, and samples were incubated for 20 minutes at room temperature
to finally read absorbance at 660 nm. Results are expressed in nmol/PO4.
Membrane fluidity of erythrocyte ghosts and submitochondrial membrane in platelets was
performed once obtained by centrifuging whole blood from patients at 4°C for 15 minutes at
3500 rpm. Supernatant was removed from the residue and 200 μL of cold buffer was added
(NaCl 140 mM, KCl 4.7 mM, MgCl 1.2 mM, KH2PO4 1.2 mM, dextrose 11 mM and HEPES 15
mM), and homogenized. Platelets (70 μL) were isolated and stored at −80°C. Evaluation of
membrane fluidity was performed by incorporation of 1,3‐dipyrenylpropane (DPyP) to
biological membranes [14]. Two milliliters of Tris‐HCL buffer with a pH of 7.8 (10 mM) was
added to 35 μL of the mitochondrial membranes and mixed at 24°C. Using fluorescent
spectrophotometer (Perkin Elmer L550B), the fluorescent intensity of the monomer (Im) and
excimer (Ie) were measured at 395 and 494 nm, respectively. Immediately, 5 μL (0.1 μg) of DPyP
was added and incubated at room temperature in darkness for 3 hours, in order to allow the
incorporation of the DPyP to membranes. The second measurement was performed at the same
wavelengths and the Ie/Im ratio of the fluorescence intensity was calculated.
2.5. Ethical considerations
Study was approved by the Research and Ethics Committee of the Health Science University
Center, University of Guadalajara, Mexico. Identification codes were assigned to each partic‐
ipant to guarantee patient confidentiality, and an informed consent form was signed before
entering the protocol, according to national and international laws (National Institutes of
Health) with clinical trial identifier NCT02129231 and also as stipulated by the Helsinki
Statements in 2000.
2.6. Statistical analysis
Sample size determination was described elsewhere [15] taking into account a 95% confidence
interval, 80% potency, and two‐tailed p < 0.05, which resulted in 21 for each group. Quantitative
variables were expressed as mean ± standard deviation. Wilcoxon tests were realized before
and after measurements, and Kruskal‐Wallis with Mann‐Whitney´s U test as post hoc analysis
for between‐group comparisons. Qualitative variables were expressed as frequencies and
percentages. The McNemar test was used to evaluate differences in dichotomy variables before
and after treatment, between‐group comparisons were determined by Fisher´s exact test and
χ2 as needed. The significance level was established with p-value <0.05.
3. Results
In the scrutiny phase, 155 patients were assessed, of which 63 were not eligible and 98 were
included as follows: placebo 24, ubiquinone 24, ezetimibe/simvastatin 25, and rosuvastatin 25
(Figure 1).
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Figure 1. Flow diagram for patients follow‐up.
Demographic features were homogeneous at baseline without significant differences between
groups. Notably, there were a greater number of women above 50 years old and more than 10
years with T2DM. Overweight and obesity was found in all treatment groups (Table 1).
3.1. Mitochondrial function markers
F0‐F1‐ATPase in HS was 236.80 ± 118.42 nmol/PO4, those with placebo had 416.23 ± 38.39 nmol/
PO4 (p = 0.094 vs. HS), for ubiquinone 535.86 ± 65.14 nmol/PO4 (p < 0.05 vs. HS), ezetimibe/
simvastatin 447.09 ± 56.91 nmol/PO4 (p = 0.065 vs. HS), and rosuvastatin with 463.37 ± 47.07
nmol/PO4 (p < 0.05 vs. HS). There was no significant difference between treatment groups (p
= 0.583, Kruskal‐Wallis). At the end of treatment, placebo group had 443.41 ± 42.86 nmol/PO4
(p = 0.783, baseline vs. final), ubiquinone 391.30 ± 42.08 nmol/PO4 (p = 0.823, baseline vs. final),
ezetimibe/simvastatin 328.50 ± 36.38 nmol/PO4 (p = 0.426, baseline vs. final), and rosuvastatin
group had a significant reduction with 340.61 ± 37.80 nmol/PO4 (p < 0.05, baseline vs. final;
Figure 2A).
Erythrocyte ghost membrane fluidity in HS was 0.80 ± 0.19 Ie/Im, while baseline levels on
placebo group were 0.97 ± 0.10 Ie/Im (p = 0.293 vs. HS), ubiquinone 1.05 ± 0.18 Ie/Im (p = 0.571
vs. HS), ezetimibe/simvastatin had 1.23 ± 0.30 Ie/Im (p = 0.936 vs. HS), and rosuvastatin 0.98
± 0.19 Ie/Im (p = 0.936 vs. HS); moreover, no significant differences were observed between
treatment groups (p = 0.632, Kruskal‐Wallis). After treatment period, there was no evident
change in either group with placebo 1.13 ± 0.31 Ie/Im (p = 0.836, baseline vs. final), ubiquinone
1.21 ± 0.25 Ie/Im (p = 0.245, baseline vs. final), ezetimibe/simvastatin 1.14 ± 0.19 Ie/Im (p = 0.983
baseline vs. final), and rosuvastatin 0.99 ± 0.17 Ie/Im (p = 0.778, baseline vs. final), without
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difference between groups (p = 0.837, Kruskal‐Wallis). There was no change in membrane
fluidity after 16‐week treatment, probably due to short‐period intervention or this particular
membrane property is not involved y pathogenic alterations noted in DM patients (Figure 2B).
Placebo (n=24) Ubiquinone (n=24) Ezetimibe/
Simvastatin (n=25)
Rosuvastatin (n=25)
Gender (M/F), n (%) 7/17 (29/71) 9/15 (38/62) 10/15 (40/60) 12/13 (48/52)
Age (years) 54.7±9.6 58.8±9.2 55.0±12.0 54.0±10.5
Weight (kilograms) 73.7±11.4 73.8±8.6 75.4±13.9 76.9±18.7
Height (meters) 1.59±0.09 1.59±0.11 1.60±0.10 1.62±0.13
BMI (kg/m2) 29.3±4.3 29.3±7.3 29.4±4.1 29.0±4.7
Type 2 DM duration
(years)
10.5±8.3 9.7±6.2 10.2±6.6 12.1±8.3
SBP (mmHg) 142±25 134±20 144±25 135±17
DBP (mmHg) 84±11 78±8 81±10 81±7
Smoking (Y/N), n (%) 9/15 (38/62) 10/14 (42/58) 8/17 (32/68) 12/13 (48/52)
Type 2 DM treatment, n (%)
 Insulin 1 (4.2) 1 (4.2) 2 (8.0)
 Metformin 5 (20.8) 5 (20.8) 5 (20.0) 4 (16.0)
 Glyburide 1 (4.2) 1 (4.0) 3 (12.0)
 Metformin/Glyburide 15 (62.5) 12 (50.0) 13 (52.0) 11 (44.0)
 Metformin/Insulin 1 (4.2) 3 (12.5) 2 (8.0) 2 (8.0)
 Metformin/Glyb/Insulin 1 (4.2) 3 (12.0)
 Others 2 (8.3) 1 (4.2) 2(8.0) 2 (8.0)
Values in mean ± SD, unless otherwise specified.
Table 1. Demographic and clinical features.
Figure 2. Mitochondrial dysfunction parameters in patients with DPN.
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Submitochondrial platelet membrane fluidity in HS had 0.38 ± 0.03 Ie/Im, with increase in
treatment groups; placebo control group had 0.68 ± 0.05 Ie/Im (p < 0.01 vs. HS), ubiquinone
0.64 ± 0.04 Ie/Im (p < 0.01 vs. HS), ezetimibe/simvastatin 0.68 ± 0.04 Ie/Im (p < 0.01 vs. HS), and
rosuvastatin 0.65 ± 0.05 Ie/Im (p < 0.01 vs. HS); however, no statistical difference between
treatment groups was found (p = 0.675, Kruskal‐Wallis). After 16‐week treatment there was no
significant change in any group, those with placebo had 0.93 ± 0.14 Ie/Im (p = 0.426, baseline
vs. final), ubiquinone 0.90 ± 0.13 Ie/Im (p = 0.057, baseline vs. final), ezetimibe/simvastatin 0.76
± 0.08 Ie/Im (p = 0.670, baseline vs. final), and rosuvastatin 0.96 ± 0.12 Ie/Im (p = 0.092, baseline
vs. final), without difference between groups (p = 0.780, Kruskal‐Wallis). There is a significant
difference in submitochondrial membrane fluidity when compared with healthy controls,
probably because of underlying pathophysiologic changes in patients with diabetes, which
cannot be resolved with short‐time treatment (Figure 2C).
3.2. Metabolic and safety profile parameters
Serum transaminases were increased on experimental groups at baseline compared with
placebo, without clinical relevance. A significant reduction in fasting glucose was noted for
placebo and ubiquinone groups, probably due to lifestyle changes; however, no difference on
HbA1c was observed. A reduction in the total bilirubin on ubiquinone and rosuvastatin
treatments was also noted (–0.16 ± 0.27 and −0.17 ± 0.31 mg/dL, respectively), without
significant difference compared with placebo. As expected, a significant reduction in TC, LDL,
and TG was detected on statins (CT‐82.8 ± 49.8 mg/dL and LDL‐57.1 ± 48.4 mg/dL for ezetimibe/
simvastatin (p < 0.001), and CT‐73.3 ± 49.5 mg/dL, LDL‐64.9 ± 44.0 mg/dL, and TG‐41.1 ± 61.2
mg/dL) (p < 0.001, p < 0.001 and p < 0.01, respectively vs. placebo) for rosuvastatin (Table 2).
Gastrointestinal, neurologic, dermatologic, and muscular adverse events related to drugs were
reported, but only two patients were eliminated from the study for myopathy related to statins
(one with ezetimibe/simvastatin and the other with rosuvastatin).
Placebo
(n=24)
Ubiquinone
(n=24)
Ezetimibe/
Simvastatin
(n=25)
Rosuvastatin
(n=25)
P (Kruskal-
Wallis)
Base
line
Final p Base
line
Final p Base
line
Final p Base
line
Final p
Glucose
(mg/dL)
186.4±
14.48
150.2±
11.2
0.004 159.5±
11.05
138.1±
11
0.020 146.64±
9.92
152.6±
14
0.620 192.04±
12.73
179.2±
15.2
0.520 0.220
Urea
(mg/dL)
29.5±
2.1
28.9±
2.2
0.520 29.23±
1.93
30.5±
2.5
0.170 30.03±
1.51
32.5±
1.9
0.280 31.22±
2.27
28.6±
2.2
0.300 0.440
Creatinine
(mg/dL)
0.79±
0.04
0.84±
0.05
0.180 0.81±
0.05
0.80±
0.05
0.840 0.82±
0.04
0.85±
0.05
0.570 0.84±
0.04
0.80±
0.04
0.320 0.750
AST (U/L) 21.9±
1.89
21.8±
1.4
0.820 27.22±
2.5
28±
2.4*
0.400 24.63±
0.99
27.1±
2.5*
0.270 27.8±
1.91
26.7±
1.2^
0.700 0.020
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Placebo
(n=24)
Ubiquinone
(n=24)
Ezetimibe/
Simvastatin
(n=25)
Rosuvastatin
(n=25)
P (Kruskal-
Wallis)
Base
line
Final p Base
line
Final p Base
line
Final p Base
line
Final p
ALT (U/L) 20.2±
1.43
20.5±
1.9
0.990 29.5±
4.88
30.3±
3.3*
0.730 28.57±
3.26
28.4±
3.1*
0.570 31.22±
2.47
30.3±
2.4^
0.870 0.010
GGT (U/L) 34.73±
6.49
39.4±
8.6
0.270 55.22±
12.98
59.6±
17.9
0.600 39.83±
9.04
33.7±
3.7
0.780 44.33±
6.93
43.9±
7.7
0.260 0.800
Total
Bilirubin
(mg/dL)
0.70±
0.06
0.56±
0.05
0.052 0.77±
0.06
0.63±
0.08
0.030 0.61±
0.04
0.64±
0.06
0.800 0.83±
0.05
0.65±
0.07
0.020 0.790
Direct
bilirubin
(mg/dL)
0.11±
0.01
0.11±
0.01
0.780 0.12±
0.02
0.15±
0.03
0.290 0.10±
0.01
0.13±
0.01
0.080 0.15±
0.02
0.13±
0.02
0.420 0.830
Total
cholesterol
(mg/dL)
211.43
±11.73
202.3
±8
0.610 230.17
±9.89
227.1±
8.3
0.330 210.56
±9.94
129.3±
9.7¥
0.001 217.2±
8.04
142.7±
8.8¥
0.001 0.001
Low
density
cholesterol
(mg/dL)
126.68
±8.76
109.6±
7.8
0.010 134.19
±8.08
132.5±
8.8
0.790 117.45
±7.16
61.7±
6.1¥
0.001 133.56
±7.96
75±
8.1¥
0.001 0.001
HDL
cholesterol
mg/dL)
36.95
±2.61
39.7±
2.5
0.470 43.95±
3.69
43.4±
3.9
0.300 36.23±
2.06
32.7±
2.1
0.090 36.79±
1.91
36.5±
2.3
0.360 0.060
Trigly
cerides
(mg/dL)
240.13
±27.41
242.4 0.590 260.25
±36.59
263.1±
37.9
0.550 234.63
±49.96
161.9±
21.2*
0.055 220.6±
24.49
168.4±
24.4*
0.003 0.005
CPK (U/L) 82.21±
13.78
82.8±
10.3
0.930 101.74±
18.42
00±
13.1
0.990 95.92±
14.4
86.4±
8.3
0.460 114.93
±18.44
157.3±
35.1
0.190 0.100
A1c (%) 8.83±
0.36
9.2±
0.5
0.260 8.49±
0.36
7.9±
0.3
0.090 7.84±
0.32
8.1±
0.4
0.250 8.97±
0.40
9.4±
0.4∞
0.090 0.030
Median ± Standard error *p<0.05 ^p<0.01 ¥p<0.001 vs. Placebo ∞p<0.01 vs. Ubiquinone (Mann‐Whitney´s U test).
A1c, glycated hemoglobin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatinine kinase;
GGT, gamma glutamyl transferase; HDL, high‐density cholesterol; LDL, low density cholesterol.
Table 2. Metabolic characteristics.
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4. Discussion
Oxidative stress generates many of the pathophysiologic changes found in T2DM [16];
furthermore, free radical excessive production is involved in axonal degeneration and
segmental demyelinization found in T2DM patients with DPN [17, 18]. Mitochondrial
biogenesis is a complex process that involves more than 100 proteins coded by the nucleus and
requires coordination with synthesis of 13 proteins coded by mitochondrial DNA. The integrity
of this process is essential for normal oxidative phosphorylation, primary source of ATP
production, O2‐, H2O2, and other ROS, which plays a fundamental role in the initiation and
progression of diabetes. These products can overregulate the expression of proinflammatory
cytokines and unchain death signals [19]. Mitochondria are very efficient by using glucose
substrates to produce energy in the form of ATP. In this process, protons are pumped from the
mitochondrial matrix to cross the inner mitochondrial membrane through the respiratory
complexes forming the oxidative phosphorylation chain. Five complexes are implicated in ATP
synthesis, culminating in complex V or ATP‐synthase, and an inverse process occurs at the
same time, named as ATP hydrolysis. An increase in F0F1‐ATP hydrolysis has been found in
rats with induced DM, probably induced by mitochondrial dysfunction [20], just as seen in
treatment groups before intervention. Rosuvastatin demonstrated a reduction in F0F1‐ATP
hydrolysis after 16‐week period, probably by reducing free radical production through
improvement of NAD(P)H oxidase [21], constituting the first study to report this finding. We
suppose an improvement in mitochondrial function by reduction in its catabolism, and
probably reducing cell apoptosis.
The most important functions of erythrocyte membrane include (a) enzymatic activity, (b) ion
transport of ions and anionic substances, (c) osmotic stability, (d) oxygen diffusion, and (e)
membrane receptor activity, where a change in elasticity results in the deterioration of blood
flow and worsens tissue perfusion [22]. Membrane fluidity of erythrocyte ghosts was slightly
increased in patients with diabetes compared with HS. After intervention, all patients maintain
almost the same values, probably due to T2DM chronicity, short‐time treatment period,
and/or not enough doses to improve this membrane property. In 2002, Koter et al. demon‐
strated a reduction in membrane fluidity with atorvastatin after 12 weeks of treatment in 31
hypercholesterolemic subjects [23]; however, T2DM consists in more complex physiopatho‐
logic components than lipid alterations as a single insult. More profound research must be
conducted to establish the exact mechanisms that can be restored in order to improve eryth‐
rocyte membrane fluidity.
Submitochondrial particles are primarily composed of the internal mitochondrial membrane
where oxidative phosphorylation and other enzymes are involved as metabolite carriers.
Patients with T2DM had upper levels of platelet submitochondrial membrane fluidity when
compared with HS, along with an increase after intervention. Until now, this was the first time
to measure this particular platelet property. So, it is difficult to make a statement concerning
its role on the pathogenesis of DPN. Previous studies on Alzheimer disease has shown low
levels of platelet submitochondrial membrane fluidity due to increased levels of LPO [13]. So,
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we could speculate that an improvement in the mitochondrial function was achieved after
treatment in all groups; however, no significant differences were found between them.
Metabolic outcomes were as expected, whereas no changes were observed on placebo and
ubiquinone groups using statin‐reduced TC, LDL, and TG. A recently published article (IM‐
PROVE‐IT) showed that ezetimibe combined with simvastatin enhances the lipid‐lowering
effect of this statin monotherapy, with the same security [24]. This study highlights the im‐
portance of LDL reduction in the improvement of cardiovascular events. Rosuvastatin
showed a more intense reduction in LDL and TG, with an additional effect on F0F1‐ATP
hydrolysis, which raises the concern about the implication of oxidized LDL in the patho‐
physiology of T2DM microvascular complications.
A slight decrease in HbA1c was shown before and after intervention with ubiquinone, not
enough to have a statistical inference but probably a larger number of patients and/or longer
period of treatment would be needed to have a significant result. On the other hand, both
placebo and ubiquinone had significant changes in fasting plasma glucose after treatment,
probably due to tight control on lifestyle modifications. Finally, a slight increase in transami‐
nases was observed with the three experimental groups compared with placebo, but levels
were at normal range and there was no difference before and after 16‐week intervention. So,
it was considered as an incidental finding without clinically correlation.
In conclusion, patients with T2DM exhibit an increase in F0F1‐ATP hydrolysis and membrane
fluidity in erythrocytes and platelets, probably due to hypercatabolism secondary to hyper‐
glycemia. A decreased mitochondrial membrane potential, dysfunction in intramitochondrial
calcium regulation, and depletion of ATP production have been described previously;
however, this is the first time, to our knowledge, that an increase in ATP hydrolysis is reported.
These mechanisms, collectively, may lead to axon degeneration [19].
Alpha‐lipoic acid (ALA) is the only effective treatment for neuropathological changes in DPN;
for responders to initial 4‐week high‐dose (600 mg tid) administration of ALA, a subsequent
treatment with ALA (600 mg qd) over 16 weeks effectively diminished neuropathic symptoms,
whereas ALA withdrawal was associated with a higher use of rescue analgesic drugs in type
2 diabetic patients with symptomatic DPN [25]. However, ubiquinone and statins have proved
a reduction in the oxidative stress status and neuropathic pain relief in previous publications
[15, 26, 27].
We now demonstrate that all treatment groups had a diminishing effect on F0F1‐ATP hy‐
drolysis, but only rosuvastatin was found to improve mitochondrial function by significant‐
ly reducing F0F1‐ATP hydrolysis. No changes in submitochondrial platelet particles or
erythrocyte ghosts were found with this 16‐week period treatment with ubiquinone, ezeti‐
mibe/simvastatin, or rosuvastatin; more research needs to be conducted to avoid bias, such
as heterogeneity of antidiabetic drugs, lifestyle changes during the study, and reduced treat‐
ment period.
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